at a glance

GLENZOCIMAB, A FIRST-IN-CLASS DRUG FOR CARDIOVASCULAR EMERGENCIES

Acticor Biotech is a clinical stage biopharmaceutical company, spin-off from INSERM (French National Institute of Health and Medical Research) which is developing an innovative, “first in-class” treatment for thrombotic diseases, with a primary focus on Acute Ischemic Stroke.

About Us
Unmet medical needs

Stroke: a global healthcare concern

13.7 million stroke cases worldwide each year

Each year, around a million patients in Europe experience a stroke, with approximately 800,000 in the US alone. By 2035, Stroke incidence in Europe should rise by 34%.4

2nd Cause of Death

Stroke is the 2nd most common cause of deaths worldwide, resulting in an estimated 5.5 million deaths in 20161, and one of the first cause of acquired disabilities in adults.

Major Economic Impact

In the USA, stroke-related care costs reached $103 billion in 20162. In EU countries, the total annual costs of stroke are estimated at €60 billion (2017)3.

About stroke
product & pipeline

Our drug candidate: glenzocimab

Glenzocimab is initially developed as an add-on therapy to approved standard of care, thrombolysis, with or without mechanical thrombectomy, during the acute phase of Ischemic Stroke, within 4.5 hours of the onset of symptoms.

Sources

[1] Feigin, V. L., Norrving, B. & Mensah, G. A. Global burden of stroke. Circ. Res. 120, 439–448 (2017).

[2] Tarun Girotra et al., “A Contemporary and Comprehensive Analysis of the Costs of Stroke in the United States.,” Journal of the Neurological Sciences (March 15, 2020).

[3] Ramon Luengo-Fernandez et al., “Economic Burden of Stroke across Europe: A Population-Based Cost Analysis.,” European Stroke Journal (March 2020).

[4] GBD 2016 Stroke Collaborators. Global, regional and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18, 439-458 (2019).

Initial Public Offering on Euronext Growth® Paris • See details